Is AbbVie Stock About To Break Out Again?

AbbVie’s upside case now turns on one pending dosing change for the medicine that supplies close to a third of guided revenue, and management expects it to speed sales up.

AbbVie (ABBV) stock trades right at the top of its 52-week range after returning 24.5% over the trailing three months, against 3.9% for the S&P 500. That is usually the point where an upside case has already been paid for. This one has not been: the change that could speed sales up is still sitting with regulators, and the medicine it applies to supplies close to a third of guided revenue. The stock has repeatedly shown that when it re-rates, it does so quickly—logging multiple 30%-plus rallies in under two months since its 2013 spinoff.

How Much Of AbbVie Is Now One Medicine?

The medicine is SKYRIZI, the immunology biologic that carried the company past HUMIRA’s biosimilar decline. It sold $5.5 billion in the second quarter of 2026, up 24% operationally, a step down from its 29.2% operational growth in the first quarter of 2026. Management guides it to $21.7 billion for 2026 against roughly $67.6 billion for the whole company, and that company total has been raised twice in 2026, by $600 million in all, with SKYRIZI’s own guide lifted at each step. The base it lands on is strengthening: revenue of $64.4 billion over the trailing twelve months is up 10.4% year over year against a three-year average of 4.9%, an acceleration on its own history, and the operating margin of 33.9% is the best of those three years. Growth that shows up in the margin like that is one of the qualities the Trefis High Quality Portfolio looks for in its holdings.

What A Subcutaneous Starting Dose Changes In Crohn’s

SKYRIZI’s fastest-growing use is in IBD, and the piece not yet in the numbers is a subcutaneous induction option for Crohn’s disease, now under review, with a decision expected in the fall of 2026. The clinical case is unusually strong: endoscopic response and clinical remission each ran 25 points above placebo across the study population and 45 points above it in patients who had never had an advanced therapy. The commercial case is duller and more persuasive. A starting dose given under the skin spares a physician from working across two different reimbursement channels, one medical and one pharmacy, and management expects a meaningful acceleration in SKYRIZI sales once the option is available.

Commercial Impact Expected By Early 2027

The honest part is the timing: by the company’s own account, contracts take a few months to catch up, so the sales effect turns up early in 2027 rather than in the second half of 2026. The competitive question to carry until then is a new oral rival launched in March. So far it looks contained: the company says the share it has taken has come mostly from the two other orals, while SKYRIZI’s own new and switching starts in the psoriasis market – a different indication from the Crohn’s filing – have grown since that launch. Those new starts are the number to watch, and a third straight raise to the revenue guide would be the confirmation; our screen of companies whose guidance keeps climbing is where that shows up first.

A Third Of The Revenue Rests On One Medicine

A growth driver this concentrated provides substantial operating leverage, but also means any regulatory or commercial shift carries significant weight for the stock. Holding growth of that kind inside a rules-based basket of quality names is a different proposition from carrying it alone. That portfolio has a track record of outpacing the three major indices.